Senseonics is in the medical diagnostics and research industry and is in the healthcare sector. The company CEO is Timothy T. Goodnow. Senseonics Inc is a medical technology company engaged in designing, development and commercialization of glucose monitoring systems for diabetes patients.

Previous Intraday Performance:

The SENS shares had a previous change of -4.79% which opened at 2.07 and closed at 1.99. It moved to an intraday high of 2.11 and a low of 1.99.

Business Wire:  Senseonics to Participate in the Guggenheim MedTech Disruptors Summit

Historical Performance:

Over the last five trading days, SENS shares returned -0.50% and in the past 30 trading days it returned -1.97%. Over three months, it changed -17.08%. In one year it has changed -39.14% and within that year its 52 week high was 5.29 and its 52 week low was 1.93. SENS stock is 3.11% above its 52 week low.

Our calculations result in a 200 day moving average of 3.09 and a 50 day moving average of 2.31. Right now, SENS stock is trading -35.54% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

Business Wire:  Senseonics to Participate in the Guggenheim MedTech Disruptors Summit


The company has a market cap of $352.2m with 177.0m shares outstanding and a float of 175.2m shares. Trading volume was 1,042,129 shares and has experienced an average volume of 1,288,360 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Senseonics was -0.6 which ended on 31st of December 2018. Based on 4 analyst estimates, the consensus EPS for the next quarter is -0.14.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019Reported 05-09-2019: -0.17
4thQtr 2018Reported 03-12-2019: -0.03
3rdQtr 2018Reported 11-08-2018: -0.18
2ndQtr 2018Reported 08-08-2018: -0.23
1stQtr 2018Reported 05-10-2018: -0.16

The long-term trend of the EPS is an important number as it indicates the present value of Senseonics; it is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 74.20% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 62.80% of institutional ownership. Short-interest was 29,158,549, which was 16.47% of shares outstanding. The short-interest ratio or days-to-cover ratio was 16.18. This stock has a moderate level of short interest, but may still be a buying opportunity depending on other indicators.

The beta was calculated to be 1.29.

Business Wire:  OvaScience and Millendo Therapeutics Provide Update on Merger Agreement and Financing

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -632.71%, return on assets is -100.92%, price-to-sales is 19.08 and price-to-book is 8.42.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 2  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here